证券之星消息，1月27日医疗美容板块较上一交易日下跌1.41%，*ST美谷领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流出4131.86万元，游资资金净流出313.41万元，散户 资金净流入4445.27万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 140.31 | -1.20% | 3.13万 | 4.39 Z | | 920982 | 锦波生物 | 228.34 | -1.31% | 5531.45 | 1.27亿 | | 688363 | 华熙生物 | 46.43 | -1.59% | 4.97万 | 2.29亿 | | 000615 | *ST美谷 | 3.19 | -2.15% | 10.89万 | 3480.46万 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 ...

编辑 | 文定 近日，一则来自淘宝店"呆瓜小伙伴"的微博在美妆圈内悄然流传。这家拥有45万粉丝、运营长达十年的个人代理老店，正式宣布将在2月底全面下架所有 商品，剩余库存正以全场7折的力度进行清仓。 近两年，从服装到美妆，一批批曾风光一时的店铺接连闭店。在平台内卷加剧、监管持续收紧、电商玩法快速迭代的多重夹击之下，电商这门生意，似乎 正变得越来越难做。 头部美妆代理店闭店 派代小编打开"呆瓜小伙伴"的店铺，发现其店内销售商品较为多样，既有珀莱雅红宝石面霜、玉泽油敏霜等知名国货美妆爆款，也有一些防晒和美妆工具 等品类，价格大多集中在几十元至百元区间，整体定位偏向平价实用派。 为保持价格吸引力，店铺还配合了平台"满200减60"、"满400减120"等促销活动。 一个值得留意的细节是，店铺中不少产品链接提供"小样装"产品，相比品牌旗舰店，这相当于为消费者提供了一个低门槛的"试用入口"，也体现出个人代 理店在货盘组织上的灵活性。不过，目前大部分商品都是售罄状态。 从数据看，这家店无疑是平台生态中的"优等生"。45.8万的粉丝数，30万+的年销量，5.0分的"宝贝质量"评分、99%的88VIP好评率，以及"小众成分护 ...

| 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 688363 华盛生物 | | 590.51万 | 2.01% | 1656.31万 | 5.63% | -2246.82万 | -7.64% | | 920982 锦波生物 | | -383.62万 | -1.73% | 491.75万 | 2.21% | -75.65万 | -0.34% | | 000615 *ST美谷 | | -746.45万 | -25.02% | 287.49万 | 9.63% | 458.96万 | 15.38% | | 300896 | 爱美客 | -1314.78万 | -2.68% | -1326.43万 | -2.71% | 2641.21万 | 5.39% | | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- ...

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, indicating strong performance compared to the market [2]. Core Insights - The cosmetics and medical beauty sector has outperformed the market recently, with the Shenwan Beauty Care Index rising by 2.0% from January 16 to January 23, 2026, surpassing the Shenwan A Index by 0.8 percentage points [4][5]. - December 2025 saw a significant increase in social retail sales for cosmetics, reaching 38 billion yuan, with a growth rate of 8.8%, indicating robust demand even in the off-season. The overall growth rate for Q4 was 9.9%, significantly higher than the annual growth of 5.1% for 2025, driven by promotional events like Double 11 [10][17]. - The report anticipates continued high consumer demand in Q1 2026, supported by new product launches and regulatory approvals in the medical beauty sector [10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown strong performance, with the Shenwan Cosmetics Index increasing by 2.6% and the Shenwan Personal Care Index rising by 4.2%, both outperforming the Shenwan A Index [4][5]. Key Company Reviews - Lin Qingxuan (2657HK) is highlighted as a benchmark in the high-end domestic skincare market, with revenue projected to grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a CAGR of 32.7%. The company is expected to turn a profit of 187 million yuan in 2024, a 120% increase year-on-year [11][12]. - Langzi Co., Ltd. (002612.SZ) forecasts a net profit of 900 million to 1.05 billion yuan for 2025, reflecting a year-on-year growth of 245.25% to 302.80% [4]. - Qingsong Co., Ltd. (300132.SZ) anticipates a net profit of 130 million to 165 million yuan for 2025, with a growth rate of 137.73% to 201.74% [4]. Market Trends - The report notes that the high-end skincare market is expanding, with the market size expected to reach 218.5 billion yuan by 2029. The concept of "oil-based skincare" is becoming mainstream, driving growth in the facial oil segment, which is projected to grow at a CAGR of 42.8% from 2019 to 2024 [12][14]. - E-commerce channels are increasingly important, with Lin Qingxuan achieving a 65.4% online revenue share in H1 2025, leveraging platforms like Douyin and Tmall for growth [13]. Sales Data - In December 2025, the total retail sales of cosmetics reached 38 billion yuan, with a year-on-year growth of 8.8%. The overall retail sales for cosmetics in 2025 were 465.3 billion yuan, reflecting a 5.1% increase [17][21].

| 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资净流入 (元) 游资净占比 散户净流入 (元) 散户净占比 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 920982 锦波生物 | | | 777.78万 | 4.57% | -145.86万 | -0.86% | 838.00 | 0.00% | | 688363 华熙生物 | | | 486.39万 | 2.47% | -2118.96万 | -10.76% | 1632.57万 | 8.29% | | 000615 *ST美谷 | | | -501.91万 | -21.98% | 111.70万 | 4.89% | 390.21万 | 17.09% | | 300896 | 爱美客 | | -567.61万 | -1.31% | -1527.19万 | -3.53% | 2094.79万 | 4.84% | 证券之星消息，1月23日医疗美容板块较上一交易日上涨1.5%，华熙生物领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收 ...

证券之星消息，1月22日医疗美容板块较上一交易日下跌1.35%，锦波生物领跌。当日上证指数报收于 4122.58，上涨0.14%。深证成指报收于14327.05，上涨0.5%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.34 | 1.52% | 6.09万 | 2015.48万 | | 688363 | 华熙生物 | 45.54 | -0.76% | 2.88万 | 1.32 Z | | 300896 | 爱美客 | 141.60 | -2.07% | 3.12万 | 4.46 乙 | | 920982 | 锦波生物 | 226.99 | -2.21% | 7993.54 | 1.83亿 | | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- ...

近期，曾凭借"玻尿酸龙头"光环市值破千亿的华熙生物，正陷入一场资本与业绩的双重考验。股东频繁 减持、业绩连续下滑、市值大幅缩水，这家曾经的行业明星企业，正试图通过"断腕"式调整寻找生机。 然而，走出低谷的道路依然布满荆棘。 一、股东密集减持，资本"用脚投票" 自2024年10月起，华熙生物第二大股东国寿成达频繁减持公司股份，持股比例从7.15%一路降至 4.01%。截至2025年1月，其通过两次大规模减持累计套现约7.69亿元。如此集中且巨额的减持行为，被 市场视为强烈的资本"离场"信号，反映出机构投资者对公司短期前景的谨慎态度。 股东减持往往不是孤立行为，其背后通常隐含着对公司成长性、行业竞争力或治理结构的隐忧。在业绩 承压的背景下，大股东减持进一步动摇了市场信心，加剧了股价下行压力。截至最近收盘，华熙生物总 市值已萎缩至约222亿元，与千亿巅峰相距甚远。 二、业绩持续探底，"瘦身"能否换来"强身"？ 财务数据显示，华熙生物的营收与净利润已进入下行通道。2024年营收同比下降11.61%，归母净利润 暴跌70.59%；2025年前三季度营收继续下滑18.36%，净利润同比下降30.29%。尽管2025年第二 ...

值得关注的是，华熙生物中试转化平台以 "行业级基础设施" 定位向全社会开放，通过成果转让、合作 开发、委托中试等模式，为高校、科研院所、初创企业提供全链条中试转化服务，推动"政产学研金服 用"深度融合。 此次五星认证的落地，是国家加速生物制造产业布局的重要信号。2025年6月，工信部与国家发改委联 合发文，明确到2027年培育20个以上生物制造中试平台。作为第四次工业革命的重要标志，生物制造已 成为全球产业竞争焦点，预计2030年全球市场规模将突破3900亿美元。华熙生物表示，未来将持续发挥 平台枢纽作用，助力我国生物制造产业在全球竞争中抢占先机。 关键词阅读：华熙生物责任编辑：栎树 近期，工业和信息化部首批《生物制造中试能力建设平台名单》公示收官，华熙生物科技（天津）有限 公司凭借全球规模领先的合成生物中试平台成功入选，并获最高"五星"等级认证。该企业成为全国仅有 的5家五星单位之一，且在化妆品、食品添加剂、生物制药三大核心领域同时拿下最高认证，标志着我 国生物制造领域中试基础设施建设取得关键突破。 中试平台是破解生物制造科研成果转化"死亡之谷"的核心枢纽。数据显示，我国科技成果转化率仅约 10%，远低于欧 ...

证券之星消息，1月20日医疗美容板块较上一交易日下跌1.35%，*ST美谷领跌。当日上证指数报收于 4113.65，下跌0.01%。深证成指报收于14155.63，下跌0.97%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | | -1111.61万 | -31.80% | 418.42万 | 11.97% | 693.19万 | 19.83% | | 920982 锦波生物 | | -2590.37万 | -17.44% | -1422.32万 | -9.57% | -129.57万 | -0.87% | | 688363 华熙生物 | | -3188.83万 | -19.82% | 950.94万 | 5.91% | 2237.89万 | 13.91% | | 300896 | 爱美客 | -5725.79万 | -13.12% | 1168.56万 | ...

Core Insights - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can help optimize industrial structures and transform economic models [1]. Group 1: Current State and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current status and trends in biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this field [5]. Group 2: Policy Landscape - The white paper discusses major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. Group 3: Industry Map and Applications - It provides a comprehensive map of the Chinese biomanufacturing industry and analyzes the industry chain along with key application directions, including biomanufacturing in pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The report identifies ten leading enterprises in the Chinese biomanufacturing sector, detailing their contributions and roles within the industry [5][6]. Group 5: Company Strategies - It outlines the synthetic biology strategies of 15 listed companies, summarizing their development approaches and corresponding popular products [5][6]. Group 6: Investment and Challenges - The white paper reviews the investment and financing situation in domestic synthetic biology from 2024 to mid-2025 and discusses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [5][6].